Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07128082 · ClinicalTrials.gov registry record · Phase 2
The Long COVID Treatment Trial
A Phase 2 study of Long COVID, sponsored by Scripps Translational Science Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT07128082: Active Phase 2 study of Long COVID, sponsored by Scripps Translational Science Institute.
NCT07128082 is a Phase 2 study of Long COVID that is active but no longer recruiting, run by Scripps Translational Science Institute. The registered enrollment target is 1,000 participants, below the 2,168-participant average among 50 other Long COVID trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07128082, a Phase 2 study of Long COVID, is active but no longer recruiting, sponsored by Scripps Translational Science Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to determine whether a medicine called tirzepatide, also called Zepbound, can reduce symptoms of Long COVID. A randomized control trial will allow us to measure the effect of the treatment by having half of the participants take the medication and half take a placebo that has no medication. Participants will take the medication (or placebo) they are given and complete study surveys for 12 months. All of the study tasks are done remotely from the comfort of a participants home.
Primary Outcome
The average difference in Fatigue Severity Scale (minimum score 9, maximum score 63, with higher scores indicating worse fatigue) between treatment and control groups of adults with Long COVID at month 3 or month 12 after study start
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Study Locations (1)
California
- Scripps Research - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-10-30 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT07128082 still lists
NCT07128082 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 2,168-participant average among 50 other Long COVID trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Long COVID appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07128082 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07128082 about?
NCT07128082 is a clinical study titled "The Long COVID Treatment Trial". The goal of this study is to determine whether a medicine called tirzepatide, also called Zepbound, can reduce symptoms of Long COVID. A randomized control trial will allow us to measure the effect of the treatment by having half of the participants take the medication and half take a placebo that h...
What is the current status of trial NCT07128082?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1,000 participants. The study started on 2025-10-30. Estimated completion is 2026-12.
What conditions does trial NCT07128082 study?
This clinical trial studies the following conditions: Long COVID.
What interventions are being tested in trial NCT07128082?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT07128082?
This trial is sponsored by Scripps Translational Science Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07128082 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long COVID
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07128082's enrollment target sits among peer trials
1,000 2nd of 50 the highest of 50 other Long COVID trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Long COVID trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NE3107 in Adults With Neurological Symptoms of Long COVID
RECRUITING · Phase 2
-
Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)
RECRUITING · Phase 2
-
Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation
RECRUITING · Phase 2
-
AT1001 for the Treatment of Long COVID
RECRUITING · Phase 2
-
LIFT: Life Improvement Trial
RECRUITING · Phase 2
-
A Study to Examine Anktiva for the Treatment of COVID-19.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI